Ontology highlight
ABSTRACT:
SUBMITTER: Regules JA
PROVIDER: S-EPMC5408576 | biostudies-literature | 2017 Jan
REPOSITORIES: biostudies-literature
Regules Jason A JA Beigel John H JH Paolino Kristopher M KM Voell Jocelyn J Castellano Amy R AR Hu Zonghui Z Muñoz Paula P Moon James E JE Ruck Richard C RC Bennett Jason W JW Twomey Patrick S PS Gutiérrez Ramiro L RL Remich Shon A SA Hack Holly R HR Wisniewski Meagan L ML Josleyn Matthew D MD Kwilas Steven A SA Van Deusen Nicole N Mbaya Olivier Tshiani OT Zhou Yan Y Stanley Daphne A DA Jing Wang W Smith Kirsten S KS Shi Meng M Ledgerwood Julie E JE Graham Barney S BS Sullivan Nancy J NJ Jagodzinski Linda L LL Peel Sheila A SA Alimonti Judie B JB Hooper Jay W JW Silvera Peter M PM Martin Brian K BK Monath Thomas P TP Ramsey W Jay WJ Link Charles J CJ Lane H Clifford HC Michael Nelson L NL Davey Richard T RT Thomas Stephen J SJ
The New England journal of medicine 20150401 4
<h4>Background</h4>The worst Ebola virus disease (EVD) outbreak in history has resulted in more than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials of an attenuated, replication-competent, recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate designed to prevent EVD.<h4>Methods</h4>We conducted two phase 1, placebo-controlled, double-blind, dose-escalation trials of an rVSV-based vaccine candidate expressing the glycoprotein of a Zaire strain o ...[more]